VYCOOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
VYCOR MEDICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.07+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $2.24M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
83.8%−4.6 pts over 5 years
Operating margin
1.8%+65.5 pts over 5 years
Net margin
-3.9%+68.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +17.2% | +15.1% | +10.3% | +5.0% | |
| Gross profit | +9.7% | +13.0% | +9.1% | +4.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -295.2% | 49.3% | 1.9% | |
| Return on assets | -94.2% | -79.1% | -7.9% | |
| Current ratio | 0.36 | 0.17 | 0.12 | |
| Debt to equity | – | -0.08 | -0.03 | |
| Net debt to EBITDA | – | -0.16× | 0.52× | |
| Inventory turnover | 0.7× | 0.7× | 2.0× | |
| Capex to revenue | 4.0% | 5.4% | 0.3% | |
| Diluted shares | 11M | 26M | 33M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vycor Medical generated $341.40K from operations and spent $61.13K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$341.40K
Used
$61.13K
Capital expenditure$61.13K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.9%
×Asset turnover2.04×
×Equity multiplier-0.24×
=Return on equity, FY20251.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3.9% | 2.04× | -0.24× | 1.9% |
| FY2024 | -6.7% | 1.60× | -0.28× | 3.1% |
| FY2023 | -4.8% | 1.58× | -0.30× | 2.2% |
| FY2022 | -33.1% | 1.36× | -3.29× | 148.4% |
| FY2021 | -31.3% | 1.45× | 4.64× | -210.5% |
| FY2020 | -72.0% | 1.10× | -0.62× | 49.3% |
| FY2019 | -57.2% | 1.30× | -1.01× | 75.0% |
| FY2018 | -91.4% | 1.21× | -3.63× | 401.3% |
| FY2017 | -106.6% | 0.94× | 53.35× | -5370.7% |
| FY2016 | -113.7% | 0.83× | 3.13× | -295.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$72.43K
- Cash generatingOperating cash flow above zero-$13.47K
- Return on assets improvedROA up on the prior year-10.8% → -7.3%
- Earnings backed by cashOperating cash flow above net income-$13.47K vs -$72.43K
- Less leverageLong-term debt to assets fell14.0% → 16.4%
- Better liquidityCurrent ratio rose0.14 → 0.12
- No dilutionShare count did not rise33M → 33M
- Gross margin improvedGross margin up on the prior year89.50% → 83.78%
- More efficientAsset turnover rose1.60 → 1.87